结直肠癌中的伴随性和突变。
Concomitant and mutations in colorectal cancer.
作者信息
Midthun Lauren, Shaheen Shagufta, Deisch Jeremy, Senthil Maheswari, Tsai James, Hsueh Chung-Tsen
机构信息
Department of Internal Medicine, Loma Linda University, Loma Linda, California, USA.
Division of Oncology, Stanford Medical Center, Stanford, California, USA.
出版信息
J Gastrointest Oncol. 2019 Jun;10(3):577-581. doi: 10.21037/jgo.2019.01.10.
Abstract
and are two key oncogenes in the RAS/RAF/MEK/MAP-kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations in both and genes have been identified in colorectal cancer (CRC). The clinical outcome of these patients remains undetermined. We present the clinical course of two patients with CRC harboring mutations at codon 12 of and non-V600E mutations. More research is needed to determine the clinical-pathological effect of these simultaneous mutations of and in CRC on disease course and treatment outcome.
摘要
[原文中未明确提及的两个基因]和[原文中未明确提及的另一个基因]是RAS/RAF/MEK/MAP激酶信号通路中的两个关键致癌基因。虽然之前认为二者相互排斥，但在结直肠癌（CRC）中已发现这两个基因同时发生突变。这些患者的临床结局仍未确定。我们报告了两名患有CRC且[原文中未明确提及的第一个基因]密码子12发生突变和[原文中未明确提及的第二个基因]非V600E突变患者的临床病程。需要更多研究来确定CRC中[原文中未明确提及的第一个基因]和[原文中未明确提及的第二个基因]同时突变对疾病进程和治疗结果的临床病理影响。
相似文献
1
Concomitant and mutations in colorectal cancer.
J Gastrointest Oncol. 2019 Jun;10(3):577-581. doi: 10.21037/jgo.2019.01.10.
2
Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.
3
Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
World J Gastroenterol. 2019 Feb 21;25(7):808-823. doi: 10.3748/wjg.v25.i7.808.
4
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Indian J Cancer. 2019 Apr-Jun;56(2):176-179. doi: 10.4103/ijc.IJC_430_18.
5
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
Oncotarget. 2015 Aug 28;6(25):20785-800. doi: 10.18632/oncotarget.4750.
6
BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
J Pathol. 2008 Feb;214(3):320-7. doi: 10.1002/path.2295.
7
[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):579-83. doi: 10.3760/cma.j.issn.0529-5807.2012.09.002.
8
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Int J Cancer. 2010 Dec 1;127(11):2569-75. doi: 10.1002/ijc.25265.
9
KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Oncol Rep. 2011 Jun;25(6):1691-7. doi: 10.3892/or.2011.1217. Epub 2011 Mar 17.
10
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
引用本文的文献
1
A compilation of 13 patients with metastatic colorectal cancer and concomitant and family mutations.
Front Oncol. 2025 Aug 25;15:1621412. doi: 10.3389/fonc.2025.1621412. eCollection 2025.
2
Colorectal Cancer: Therapeutic Approaches and Their Complications.
Biomedicines. 2025 Jul 5;13(7):1646. doi: 10.3390/biomedicines13071646.
3
Clinicopathological Features of KRAS-Mutated Colon Cancer: An Analytical Cross-Sectional Study.
Gastroenterology Res. 2025 Jun 16;18(4):175-181. doi: 10.14740/gr2032. eCollection 2025 Aug.
4
The complex journey of targeting RAS in oncology.
BMC Cancer. 2025 Jul 1;25(1):1053. doi: 10.1186/s12885-025-14033-y.
5
V600E mutation associated with papillary high-grade serous ovarian cystadenocarcinoma in a 22q11.2DS patient.
Gynecol Oncol Rep. 2025 May 28;59:101776. doi: 10.1016/j.gore.2025.101776. eCollection 2025 Jun.
6
Advances in antitumour therapy with oncolytic herpes simplex virus combinations.
Discov Oncol. 2024 Jul 24;15(1):302. doi: 10.1007/s12672-024-01165-z.
7
High Probability of Lynch Syndrome Among Colorectal Cancer Patients Is Associated With Higher Occurrence of KRAS and PIK3CA Mutations.
World J Oncol. 2024 Aug;15(4):612-624. doi: 10.14740/wjon1843. Epub 2024 Jun 17.
8
Domperidone, a Dopamine Receptor D2 Antagonist, Induces Apoptosis by Inhibiting the ERK/STAT3-Mediated Pathway in Human Colon Cancer HCT116 Cells.
Biomol Ther (Seoul). 2024 Sep 1;32(5):568-576. doi: 10.4062/biomolther.2024.048. Epub 2024 Jun 25.
9
Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer.
Curr Issues Mol Biol. 2023 Dec 23;46(1):121-139. doi: 10.3390/cimb46010010.
10
Genetic Alterations of NF-κB and Its Regulators: A Rich Platform to Advance Colorectal Cancer Diagnosis and Treatment.
Int J Mol Sci. 2023 Dec 21;25(1):154. doi: 10.3390/ijms25010154.
本文引用的文献
1
Double and Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
Anticancer Res. 2018 May;38(5):2891-2895. doi: 10.21873/anticanres.12535.
2
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15.
3
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.
Ann Oncol. 2017 Nov 1;28(11):2648-2657. doi: 10.1093/annonc/mdx401.
4
Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma.
Case Rep Oncol Med. 2017;2017:2321052. doi: 10.1155/2017/2321052. Epub 2017 Jul 24.
5
Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.
Oncologist. 2017 Jul;22(7):864-872. doi: 10.1634/theoncologist.2017-0031. Epub 2017 Jun 2.
6
BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.
7
BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.
J Gastrointest Oncol. 2015 Dec;6(6):660-7. doi: 10.3978/j.issn.2078-6891.2015.077.
8
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.
9
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.
Oncotarget. 2014 Dec 15;5(23):11752-77. doi: 10.18632/oncotarget.2555.
10
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12.
Zotero 插件